Wanzhou Zhang

Wanzhou Zhang

Auto-generated profile, based on publicly available information

Wanzhou Zhang

Department of Neurology, Shenzhen Hospital, Southern Medical University, Shenzhen, 518000, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2025 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
ZDZihao Deng
Zihao Deng
YLYudi Li
Yudi Li
WCWenjun Chi
Wenjun Chi
WZWanzhou Zhang
Wanzhou Zhang
FLFangming Li
Fangming Li
LLLing Li
Ling Li
Alzheimer's disease (AD) is a chronic, progressive neurodegenerative disorder clinically characterized by memory decline, cognitive dysfunction, language impairment, deterioration of visuospatial skills, and personality changes. Pathologically, AD is marked by the deposition of β-amyloid (Aβ) plaques in the brain, the formation of neurofibrillary tangles, and progressive neuronal loss. Recent research has highlighted transfer RNA (tRNA)-derived small RNAs (tsRNAs) as crucial regulators in various biological processes; however, their roles in the pathophysiology of AD remain largely unexplored. The erythropoietin-producing hepatocellular (Eph) receptor family has recently drawn attention in the study of neurodegenerative diseases due to their role in regulating critical processes, including cell migration, neural development, angiogenesis, and tumor formation. This study aimed to investigate specific tsRNAs associated with AD by performing RNA sequencing on the cortex of APP/PS1 transgenic mice and to explore the relationship between tsRNAs and their target genes within the Eph receptor family, thereby elucidating insights into the specific regulatory functions of these molecules. Eight-month-old male C57BL/6 and APP/PS1 transgenic mice were used in the study. BV-2 and HT22 cells were cultured and treated with Aβ25-35 at concentrations ranging from 0 µM to 40 µM. RNA was extracted from cortical tissues, and tRNA-derived fragments were analyzed after pre-treatment to remove RNA modifications. Differential expression of tRFs and tiRNAs was identified through sequencing, followed by bioinformatics analysis of target genes using TargetScan and miRanda. Transfection of BV-2 and HT22 cells with EphA7-siRNA and tRFAla-AGC-3-M8-mimic was conducted, and their interaction was validated using dual-luciferase reporter assays. Protein expression levels were assessed by western blotting and immunofluorescence. Statistical analyses were performed using R and GraphPad Prism, with significance set at p < 0.05. We identified for the first time that EphA7 expression is upregulated in aggregated microglia and neuronal cells in the dentate gyrus region of the hippocampus, with increased phosphorylation of ERK1/2 and p70S6K in AD. This upregulation occurred following the downregulation of tRFAla-AGC-3-M8 due to Aβ stimulation and was confirmed via in vitro experiments. By inhibiting EphA7 expression and increasing tRFAla-AGC-3-M8 expression, we suppressed the ERK1/2-p70S6K signaling pathway in BV-2 and HT22 cells. This intervention alleviated neuronal damage and tau hyperphosphorylation in HT22 cells and reduced the M1-type polarization state of BV-2 cells induced by Aβ25-35 (see Graphical Abstract). This study clarifies the specific role of tRFAla-AGC-3-M8 in AD pathology and offers a promising target for therapeutic interventions.

16 August 2022 in Journal of Neurochemistry
Verified
Journal Article
Closed access
WZWanzhou Zhang
Wanzhou Zhang
YLYudi Li
Yudi Li
LLLing Li
Ling Li
LLLi Ling
Li Ling